This review was written to inform pediatricians and pediatric health care providers about ecstasy, GHB and ketamine, with a focus on treating adverse effects from each drug. While the paper attempts to cover a wide area of topics, from the history of MDMA to its mechanisms of action, the authors display a spotty knowledge of topics outside of treatment for medical emergencies. The strongest points of this review are the sections on the contents of ecstasy pills and recommendations for the treatment of adverse events relating to ecstasy. There are some surprising errors in the review, including statements about the effects of ecstasy that fail to rely on laboratory studies or retrospective interviews, most of which were published before 2001, and the failure to mention the chief pharmacological action of MDMA, that of a serotonin releaser. Information on fatalities after ecstasy use are not placed within the context of fatalities occurring after the ingestion of other drugs. Despite the authors' rejection of scare tactics in drug abuse education, and their support for peer education, the authors criticize organizations, such as DanceSafe, that appear to be relying on the model preferred by the authors. Criticism is leveled at MAPS for supporting MDMA in therapeutic and research contexts, apparently because the authors believe this indicates that some use of MDMA "can be safe," and they do not think this is true. However, given that at least six research teams in the US and Europe have performed clinical trials with MDMA without the occurrence of severe or life-threatening adverse events, it would seem that 1 or 2 doses of MDMA can be administered safely within a controlled clinical or laboratory setting. This review does not consistently provide accurate information on ecstasy.